Press Release

nextpharma.com

NextPharma announces the appointment of Ajeeth Enjeti as CEO to succeed Peter Burema

- **Enjeti brings extensive global experience to NextPharma**
- **Will lead a strategy focused on growth, innovation and enhanced client services**
- **Burema to take seat on Board of NextPharma post his retirement from CEO role**

NextPharma (“the Company”), a European leader in pharmaceutical Contract Development and Manufacturing, is pleased to announce the appointment of Ajeeth Enjeti as CEO, succeeding Peter Burema, who has led the company since 2014.

Enjeti will take up his new position on November 1st, 2025, and continue the implementation of NextPharma’s ambitious strategy aimed at growth, innovation and market-leading new pharmaceutical development and manufacturing solutions tailored to NextPharma’s worldwide clients. Having reached retirement, Peter Burema will step down from the role of CEO and take up a position as Non-Executive Director on the Board of NextPharma in January 2026.

Ajeeth Enjeti brings a wealth of experience across a breadth of industries to NextPharma and has an excellent track record of leading teams and organisations to deliver customer centricity, innovation, manufacturing excellence, growth and strong financial performance. Since 2021 he has served as GM and president at Trivium Packaging a global industry-leader with 57 locations and approximately 7,400 employees. Prior to that, he was Senior Vice President of Strategy and Transformation and member of the Executive Committee at Elementis PLC, a FTSE listed B2B company. Ajeeth has held a number of other senior positions with companies such as Mondo Minerals, Bain & Co., IBM and PepsiCo. Ajeeth has an MBA from IMD in Switzerland, a Master's degree in Management from University of Delhi, and a Bachelor's degree in Electrical Engineering from Delhi Technological University.

As part of its strategy, NextPharma continues to undertake significant new investment across the business as part of its commitment to provide customers with the highest quality products and services. This has recently included the expansion of its centre of excellence in Limay, France, specialised in the development and manufacture of liquid dosage forms. It is also devoting significant investment to the expansion of its facility in Tampere, Finland, specialised in the development and manufacture of ophthalmic products in a variety of dosage forms.

Commenting on the leadership transition, Othmane Khelladi, Chairman of NextPharma, said: “We are delighted to welcome an executive of Ajeeth’s calibre to the role of CEO of NextPharma. His wealth of experience and a proven track record, the quality of all our people, and the milestones and achievements delivered under Peter’s leadership, leave the Company very strongly positioned to embark on a new phase of innovation, service enhancement and growth. The Board looks forward to supporting Ajeeth and the team on this exciting journey. The Board is also deeply grateful to Peter for his vision and leadership over the last decade and we are delighted he will maintain an active interest in the business as Non-Executive Director.”

Ajeeth Enjeti, said: “I’m very proud to be joining the NextPharma team at such an exciting time and look forward to working with my new colleagues and our clients to realise our ambitious plans for the future. Following Peter’s leadership over the last decade, I know I am taking over an excellent business and look forward to building on the team’s successes to date to firmly position NextPharma as Europe’s leading Contract Development and Manufacturing Organisation (CDMO).”

Peter Burema said: “I am immensely proud of what the team and I have achieved together at NextPharma over the last decade and deeply appreciative of all those who supported me during my tenure as CEO. I know the business will continue to flourish under Ajeeth’s leadership and look forward to working with him to ensure a seamless transition and, longer-term, supporting the team as a member of the Board of NextPharma to deliver on the exciting milestones that lie ahead.”

A portfolio company of CapVest Partners LLP (“CapVest”), NextPharma is a leading European pharmaceutical Contract Development and Manufacturing Organisation (“CDMO”) with a footprint spanning five sites in Germany, two in France, one in Finland, Norway and Scotland, and with healthcare logistics services in the DACH region. NextPharma supplies products globally, with nine of its ten sites FDA-approved. With expertise in solids, semi solids and non-sterile and sterile liquids, the company provides services from pharmaceutical development, clinical supplies, scale-up and process validation through to commercial manufacturing for a large range of dosage forms including tablets, capsules, granules, powders, pellets, gels, creams, liquid-filled capsules, softgels, sprays and syrups. Additionally, it provides a wide range of packaging solutions including blow-fill-seal, blisters, bottles, sachets, stick packs and tubes. NextPharma’s expertise and centres of excellence enable it to provide a unique service offering in certain specialised areas including hormonal solids and semi-solids, cephalosporins, penicillins, chewable tablets, modified release products, lipid-based formulations (including hormonal and high potent products), as well as paediatric medicinal products.

For more information, please visit www.nextpharma.com.

Contact

Executive Assistant
hannah.scholes@nextpharma.com
Tel: +44 (0) 203 585 4120